Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986278 in Healthy Male Participants
Bristol-Myers Squibb · Healthy Volunteers
Phase 1
Completed
9
2022-06
Industry sponsor intelligence
Bristol-Myers SquibbClinical Pipeline.
Lead-sponsor view of Bristol-Myers Squibb's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 2
- Recruiting
- 0
- Active
- 0
- Completed
- 2
- Results posted
- 0
- Avg enrollment
- 25
Pipeline overview
Programs by phase and activity.
Velocity
Bristol-Myers Squibb trials by start year
Study start year · indexed snapshot
Development
Trials by phase
1phase labels
Early Phase 10
Phase 11
Phase 20
Phase 30
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Sincalide → | 1 | 1 | 0 | 0 | 0 | 0 |
| Metreleptin → | 1 | 0 | 0 | 0 | 0 | 0 |
Active peptide trials
In motion now.
No studies in this snapshot.
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
Bristol-Myers Squibb · Lipodystrophy
Not applicable
Completed
41
2015-04
Search sponsor records
All Bristol-Myers Squibb studies.
This page groups studies where Bristol-Myers Squibb is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
2 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT04567667Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986278 in Healthy Male ParticipantsJun 2, 2022NCT00677313An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With LipodystrophyApr 30, 2015